Novel immunotherapy strategies for hepatobiliary cancers

Thomas T. Deleon, Yumei Zhou, Bolni M. Nagalo, Raquel T. Yokoda, Daniel H. Ahn, Ramesh K. Ramanathan, Marcela A. Salomao, Bashar A Aqel, Amit Mahipal, Tanios S. Bekaii-Saab, Mitesh J. Borad

Research output: Contribution to journalReview article

Abstract

Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Immunotherapies that have demonstrated clinical efficacy in hepatobiliary cancers include PD-1 inhibitor therapy and CTLA-4 inhibitor therapy. Novel immunotherapy concepts include targeting emerging checkpoint proteins, bispecific T-cell engagers, combinatorial trials with checkpoint inhibitors, oncolytic virotherapy and chimeric antigen receptor T cells. The goal for these new treatment strategies is to achieve a meaningful expansion of patients deriving prolonged clinical benefit from immunotherapy.

Original languageEnglish (US)
Pages (from-to)1077-1091
Number of pages15
JournalImmunotherapy
Volume10
Issue number12
DOIs
StatePublished - Sep 1 2018

Keywords

  • biliary tract cancers
  • CAR-T-cell therapy
  • hepatocellular carcinoma
  • immunotherapy
  • oncolytic virotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Novel immunotherapy strategies for hepatobiliary cancers'. Together they form a unique fingerprint.

  • Cite this